Condition: Extrapulmonary Neuroendocrine Cancer (epNEC) · Sponsor: Boehringer Ingelheim
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein. During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works.
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-012 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | Not Yet Recruiting |
| City of Hope-Duarte-56419 | Duarte, California, United States | Not Yet Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Not Yet Recruiting |
| University of California San Francisco | San Francisco, California, United States | Not Yet Recruiting |
| University of California Los Angeles | Santa Monica, California, United States | Not Yet Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Not Yet Recruiting |
| Emory University | Atlanta, Georgia, United States | Not Yet Recruiting |
| The Skip Viragh Outpatient Cancer Research Building | Baltimore, Maryland, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Mayo Clinic, Rochester | Rochester, Minnesota, United States | Not Yet Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Not Yet Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
+ 153 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07544654